



ANALYTICAL DETERMINATION OF FUROSEMIDE: THE LAST RESEARCHES

M. Espinosa Bosch, A.J. Ruiz Sánchez, F. Sánchez Rojas, C. Bosch Ojeda

Department of Analytical Chemistry, Faculty of Sciences, University of Málaga, Campus Teatinos, 29071 Málaga, Spain

*Corresponding Author Email: fsanchezr@uma.es

ABSTRACT

Furosemide (FUR) is an anthranilic acid derivative which is a potent diuretic widely used in the treatment of congestive heart failure and edema. FUR works by blocking the absorption of salt and fluid in the kidney tubules, causing a profound increase in urine output (diuresis). Due to the considerable use of FUR, analytical determination is frequent. In this manuscript, a review of the methods developed for determination of FUR from the year 2008 is presented.

KEY WORDS

Furosemide; Review; Biological samples; Pharmaceutical

1. INTRODUCTION

Drugs that facilitate diuresis are widely used for the treatment of edematous conditions and in the management of hypertension and other conditions for which the increase in urinary flow can relieve symptoms. Diuretics are an important group of the drugs used in various clinical situations such as cardiac and renal insufficiency, nefrotic syndrome, edema, cirrhosis, and hypertension. Diuretics are substances that produce increase urinary excretion of bodily sodium bound to anions and water, thereby reducing its concentration in extracellular liquids. Furosemide (4-chloro-N-furfuryl-5-sulfamoylanthranillic acid, FUR), an effective diuretic, has been widely used in the treatment of chronic renal failure, hypertension, congestive heart failure and cirrhosis of the liver. FUR is often classified as a loop diuretic due to its predominant action in the nephron, where the drug interferes with the tubular re-absorption of sodium on Henle's loop. FUR acts inhibiting the cotransportation of sodium, potassium and chloride, and further cause's excretion of calcium, magnesium and bicarbonate ions. Intense and fast dieresis may also mask the ingestion of other doping agents by reducing their concentration in urine. For this reason, the Medical Commission of the International Olympic Committee banned the use of FUR among other diuretics in 1986.

Due to the clinical importance of FUR, a large number of analytical procedures to detect the presence of this drug in pharmaceutical and physiological samples have been developed. For example, several methods including titrimetric, optical and electrochemical detections and capillary electrophoresis have been used to quantify FUR. Also, liquid-liquid extraction, followed by solvent evaporation, has been used for sample preparation in the chromatographic analysis of diuretics in biological samples. Several reports addressed unresolved issues of precision, time consuming and loss of compounds of interest. Other researchers have proposed the use of micellar liquid chromatography for the determination of diuretics, such as FUR in pharmaceutical preparations. The literature survey revealed that HPLC has been employed to detect FUR in blood, urine, or perilymph. So far, HPLC is generally the method of choice for diuretics quantitation, due to the required time and cost of the analysis. In our previous work [1], we present the most relevant analytical methodologies used in its determination from the nineties decade at the year 2008.

www.ijpbs.com (or) www.ijpbsonline.com

This work consists of papers mainly reported from 2009 until today about the analytical methodology for FUR determination. In **Table 1** are summarized the more important aspects of the methods proposed for

the determination of FUR alone and in mixture with other compounds based in different analytical techniques.

Table 1: Analytical determinations of furosemide

Compounds	Techni	Procedure	Linear range	RSD (%)	Applications	Ref.
	que					
-	UV/VIS	Method A: 1 ml 5M H ₂ SO ₄	Method A:	Method A:	Tablets,	2
		+ 1 ml 500 μg ml ⁻¹ KMnO ₄ ;	3.0-24.0 μg	2.58	injection and	
		at 550 nm	ml ⁻¹	Method B:	combination	
		Method B: with 0.1M	Method B:	2.63	tablet	
		NaOH +1 ml 2 mg ml ⁻¹	1.25-20.0 μg			
		KMnO ₄ ; at 610 nm	ml ⁻¹			
-	UV/VIS	Acid hydrolysis of FUR and	Method A:	-	Spiked	3
		coupling with:	1.75-21.0 μg		human urine	
		Method A: N-1-	ml ⁻¹		and	
		napthylethylene diamine;	Method B:		pharmaceuti	
		at 520 nm	2.5-30.0 μg		cal	
		Method B: 4,5-	ml ⁻¹		formulations	
		dihydroxynaphthalene-2,7-				
		disulfonic acid; at 500 nm				
-	UV/VIS	1 ml 0.3% CAS + 1ml 1M	Method A: 20-	Method A:	Two	4
		H ₂ SO ₄ Method A: + 1 ml	30 μg ml ⁻¹	0.064	different	
		0.05% XC; at 612 nm	Method B: 6-	Method B:	branded	
		Method B: 2 ml 0.01%	16 μg ml ⁻¹	1.8345	tablets	
		SAF; at 526 nm				
Spironolactone	UV/VIS	Method A: 1 st deriv.	FUR: 2-10 μg	FUR: 0.29-	Combined	5
		Spironolactone: D1	ml ⁻¹ ;	1.37	tablet	
		amplitude at zero crossing	Spironolacton	spironolact	dosage form	
		point of FUR at 250.80 nm;	e: 5-25 μg ml ⁻¹	one: 0.8-		
		FUR D1 at zero crossing		1.62		
		point of spironolactone at				
		350 nm				
		Method B: Absorbance				
		ratio, from overlay spectra,				
		FUR and spironolactone				
		show an isoabsorptive				
		point at 261.21 nm, second				
		wavelength is 276 nm, λ_{max}				
		of FUR				
Spironolactone	UV/VIS	Method A: 2 nd deriv. at 238	FUR: 0.8-4.0	<2 for both	Bulk drug	6
		and 277 nm Method B:	μg ml ⁻¹	methods	and	
		area under curve at 228-	Spironolacton		pharmaceuti	
		248 and 267-287 nm	e: 2-10 µg ml ⁻¹		cal	
					formulations	

IJPBS | Volume 3 | Issue 4 | OCT-DEC | 2013 | 168-181

www.ijpbs.com (or) www.ijpbsonline.com

-	FL	In a buffer solution of	4.5- 5000 ng	<0.8	Solid	7
		KCI/HCl 50 mM (pH 2.0); at λ_{exc} 280 nm; λ_{em} 410 nm	ml ⁻¹		pharmaceuti cal forms	
-	FL	50 μl Tris/HCl buffer (pH 7.80, 0.05 M), 50 μl 0.01M bix ethanol solution, 50 μL 0.01M ZnSO ₄ , suitable amounts of FUR and 160 μL 0.01M NaCl; after that, the mixture was diluted to 500 μl with ultra-pure water, shaking several seconds using a vortex mixer; mixture was left to stand 20 min at 37 °C before measuring	0.06-7.2 μΜ	3.9	Tablets	8
Amiloride	FL	FUR: λ_{ex} 237 nm, λ_{em} 415 nm Amiloride: λ_{ex} = 365, λ_{em} = 406 nm	FUR: 1.33x10 ⁻¹ 3-4 µg ml ⁻¹ Amiloride: 3.2x10 ⁻⁴ -0.8 µg ml ⁻¹	FUR: <1.23 Amiloride: <1.36	Pharmaceuti cal formulations	9
Amiloride	FL	FUR: λ_{ex} 237 nm, λ_{em} 415 nm Amiloride: λ_{ex} = 365, λ_{em} = 406 nm	FUR: 1.2x10 ⁻³ - 4 μg ml ⁻¹ Amiloride: 3.7x10 ⁻⁴ -0.8 μg ml ⁻¹	In spiked human urine FUR: 1.56-5.21 Amiloride: 1.41-3.76	Urine	10
-	DRS	Onto 2.25 cm ² filter papers (Whatman No. 1), 20 µL of the chromogenic eagent solution was spotted, followed immediately by addition of 20 µL of FUR; at 477 nm	1.65-9x10 ⁻³ M	<2	Urine	11
-	DPV	In methanol:water (10:90) at pH 4.8 with 0.04M Britton-Robinson buffer as supporting electrolyte at 25 °C	6x10 ⁻⁶ -8x10 ⁻⁴ M	1.217	Tablet dosage form	12
-	Potenci ometry	(-)Ag/AgCl/[NaCl]=0.01M; [NaNO ₃]=0.490M//[NaFur] =xM;[NaNO ₃](0.500-x) M/Graphite/Hg ₂ (Fur) ₂ /Hg/P t(+)	5x10 ⁻⁷ -1x10 ⁻² M	In tablets	Pharmaceuti cals, urine, blood serum and bovine milk	13
-	DPV	In 5.0 pH with 0.04 M Britton—Robinson buffer as	8x10 ⁻⁶ -2x10 ⁻⁴ M	3.54	Pharmaceuti cals and	14

www.ijpbs.com (or) www.ijpbsonline.com

	1	cupporting	T		urine	
		supporting			urine	
		electrolyte at 25 °C at a				
	1151.0	CNTPE	0.000.40.00		5	4-
-	HPLC-	IS: nitrazepam; Lichrospher	0.020-10.00	-	Rat plasma	15
	UV	C ₁₈ ; A: KH ₂ PO ₄ 10 mM, pH	μg ml ⁻¹			
		2.5 (with H ₃ PO ₄ 85%)				
		B: Acetonitrile				
		Gradient elution:				
		0.00-18.00 min 77% A, 23%				
		В				
		18.01-25.00 min 10% A,				
		90% B				
		25.01-29.00 min 77% A,				
		23% B;				
		at 2 ml min ⁻¹ ; column				
		temperature 45 ⁰ C;				
		injection volume 100μl; at				
		230 nm				
-	HPLC-	Spherisorb C ₁₈ ;	5.2-25000 ng	<2	Tablets and	16
	UV	acetonitrile:10mM KH ₂ PO ₄	ml ⁻¹		nanoparticle	
		(70:30) pH 3.85; at 1 ml			S	
		min ⁻¹ ; at room				
		temperature; at 233 nm				
-	HPLC-	Spherisorb C ₁₈ ; 10 mM	0.5-50 μg ml ⁻¹	<2	Solubility	17
	UV	KH ₂ PO ₄ (pH 5.5):methanol			studies	
		(70:30); at 1 ml min ⁻¹ ; at				
		235 nm				
Amiloride	HPLC-	HIQ SIL C ₁₈ ; 50mM	FUR: 20-200	FUR: 0.072	Tablets	18
	UV	phosphate	μg ml ⁻¹	Amiloride:		
		buffer:acetonitrile (50:50)	Amiloride: 10-	0.754		
		pH 3.0; at 1 ml min ⁻¹ ; at	100 μg ml ⁻¹			
		25ªC; at 283 nm				
Amiloride	HPLC-	Inertsil C ₁₈ ; methanol:0.1%	FUR: 800-2800	FUR: <2.6	Human	19
	UV	glacial acetic acid	ng ml ⁻¹	Amiloride	plasma	
		(43:57) pH 5.05 adjusted	Amiloride:	<2.1		
		with NaOH; at 1 ml min ⁻¹ ;	100-350 ng			
		at 226 nm	ml ⁻¹			
Spironolactone	HPLC-	Hiber C ₁₈ ;	FUR: 2-10 μg	FUR: 0.09-	Combined	20
	UV	acetonitrile:water; at 1 ml	ml ⁻¹	1.181	pharmaceuti	
		min ⁻¹ ; at room	Spironolacton	Spironolac	cal dosage	
		temperature; at 237 nm	e: 5-25 µg ml ⁻¹	tone:	form	
				0.863-		
				1.585		
Spironolactone	HPLC-	Inertsil C ₁₈ ;	FUR: 10-60 μg	FUR: 0.41-	Combined	21
	1	1	ml ⁻¹	0.00		1
	UV	methanol:water (70:30)	mı	0.99	pharmaceuti	

www.ijpbs.com (or) www.ijpbsonline.com IJPBS | Volume 3 | Issue 4 | OCT-DEC | 2013 | 168-181

		phosphoric acid; at 1 ml	e: 25-150 μg	tone: 0.60-	form	
		min ⁻¹ ; at 236 nm	ml ⁻¹	0.99		
Spironolactone	Micella	IS: indapamide; Shim-pack	FUR: 0.1-10 μg	FUR: 0.57	Combined	22
	r HPLC-	VP-ODS C ₁₈ ; 0.1M sodium	ml ⁻¹	Spironolac	pharmaceuti	
	UV	dodecyl sulphate, 0.3%	Spironolacton	tone:0.72	cal dosage	
		triethylamine, 10% n-	e: 0.4-20 µg		form and	
		propanol in 0.02 M	ml ⁻¹		human	
		orthophosphoric acid at pH			plasma	
		4.0; at 1 ml min ⁻¹ ; at 238			-	
		nm				
Gemifloxacin	HPLC-	Purospher Start C ₁₈ ;	FUR: 0.025-0.5	<0.16 in all	Bulk,	23
Hydrochlorothi	UV	methanol: water:	μg ml ⁻¹	cases	pharmaceuti	
azide		acetonitrile (70:25:5) at pH	Gemifloxacin:		cal dosage	
		3.0 with phosphoric acid	0.5-10 μg ml ⁻¹		form and	
		85%; at 0.8 ml min ⁻¹ ; at	Hydrochloroth		human	
		room temperature; at 232	iazide: 0.125-		serum	
		nm	2.5 μg ml ⁻¹			
Ethacrynic acid	HPLC-	OptimaPak C ₁₈ ;	FUR: 0.5-400	FUR: 3.26	Human	24
	UV	methanol:H ₂ O (70:30); at	ng ml ⁻¹	Ethacrynic	urine	
		0.5 ml min ⁻¹ ; at 228 nm	Ethacrynic	acid: 3.74		
			acid: 1.2-200			
			ng ml ⁻¹			
Spironolactone	UHPLC-	Hypersil GOLD C ₁₈ ;	0.1-20 μg ml ⁻¹	-	Human	28
Terbinafine	UV	acetonitrile: formic acid			plasma and	
Vancomycin		0.1% in gradient; at			urine	
and their		different λ				
metabolites						
Antipyrine	HPLC-	C18, water pH 3 and 50:50	5-100 μΜ	<2	In	29
Carbamazepine	UV	methanol: acetonitrile			determining	
Phenytoin		(58:42); at 1 ml min ⁻¹ ; at			Caco-2	
		40 ⁰ C; at 205 nm			permeability	
		carbamazepine and			of markers	
		phenytoin; at 230 nm FUR				
		and antipyrine				
23 selected	HPLC-	Merck LiChroCART C ₁₈ ;	0.05-45 μg ml	1.35-5.41	Human	30
drugs	DAD	gradient elution with	¹ for all drugs		urine	
		mobile phase at various				
		proportions of				
		acetonitrile:methanol:0.05				
		% trifluoroacetic acid; in				
		the range 200-450 nm				
Metoprolol	MLC-	ODS-3 MZ C ₁₈ ; buffer	FUR: 0.5-4 μg	<9.5	Human	31
1	_					
Verapamil	UV	(0.15M SDS, 25 mM	ml ⁻¹		plasma	



www.ijpbs.com (or) www.ijpbsonline.com

	FLD	1-butanol: triethyl amine	and			
		(93:6:1); at	Verapamill:			
		40°C; at 2 ml min ⁻¹ ;	0.1-0.8 μg ml ⁻¹			
		verapamil and metoprolol				
		detected by				
		spectrofluorimeter				
		(excitation 230 nm and				
		emission 311 nm) and FUR				
		by UV detector at 240 nm				
-	HPLC-	IS: Imipramine Inersil C ₁₈ ; 5	0.03-150 μΜ	-	Paediatric	32
	FLD	mM NaH₂PO₄			samples of	
		buffer:acetonitrile (30:70)			plasma and	
		pH 3; at 1.5 ml min ⁻¹ ; at λ_{ex}			urine	
		270 and λ_{em} 470 nm				
Canrenone	LC/MS/	Reversed phase	FUR: 20-1600	<15	Human	33
Spironolactone	MS	mechanism, on a 250 mm	ng ml ⁻¹		plasma	
		length column packed with	Canrenone			
		octadecyl modified	and			
		silicagel and thermostated	Spironolacton			
		at 35 °C; under isocratic	e: 2-100 ng ml			
		conditions (3:7 aqueous	1			
		0.1% formic acid and				
		methanol); at 0.8 ml min ⁻¹				
17 diuretics	HPLC-	Capcell-pak C ₁₈ ; mobile	UV: 2.5-60 μg	UV: <3	Drug	34
	UV	phase: trifluoroacetic acid	ml ⁻¹	MS:<13	adulteration	
	LC/MS/	0.15% (A) and acetonitrile	MS: 7-70 ng		screening of	
	MS	(B); initial composition	ml ⁻¹		dietary	
		90% A - 10% B; different			supplements	
		gradient elution for UV and				
		MS; at 254 nm for UV;				
		electrospray ionisation in				
		either positive- or negative				
		ion mode				
Spironolactone	HPTLC	HPTLC plates precoated	FUR: 0.016-	<2	Tablet	35
		with 0.25 mm layer of	0.064 mg ml ⁻¹		formulation	
		silica gel mixture [Silica	Spironolacton			
		GF254] on aluminum	e: 0.040-0.160			
		sheets; ethyl acetate:	mg ml ⁻¹			
		hexane (80:20); UV				
		Scanning densitometer set				
		at 254 nm				

2. OPTICAL METHODS

2.1. Spectrophotometric methods

Due to its inherent simplicity, sensitivity and costeffectiveness, visible spectrophotometry is a technique of choice employed in quality control laboratories of many developing countries. Therefore, developing a selective and sensitive methods using visible spectrophotometry is of paramount



www.ijpbs.com (or) www.ijpbsonline.com

importance. As can be seen in the previous work [1], several spectrophotometric methods has been reported for the determination of FUR in bulk, pharmaceutical dosage forms, and/or biological fluids.

Tharpa et al. [2] describes two visible spectrophotometric methods based on the reduction of KMnO₄ in acid and basic mediums. In method A, FUR was treated with a measured excess of permanganate in acid medium and the unreacted oxidant was measured at 550 nm, whereas in method B the reaction was carried out in alkaline medium and the resulting manganate was measured at 610 nm. Simplicity, sensitivity, wide linear ranges, mild experimental conditions and above all costeffectiveness characterize the proposed methods. Further, the methods were found to possess adequate accuracy and precision. Method A is simpler can be extended successfully to the quantification of FUR present in the injections and combination tablets without interference from the other active ingredients. However, method B entails an extraction step when applied to tablets to overcome the interference from some inactive ingredients. Later, the same research group describes simple, sensitive, and selective two spectrophotometric methods for the determination of FUR [3]. The methods are based on acid hydrolysis of FUR to free primary aromatic amine and diazotization followed by coupling with N-1napthylethylene diamine (method A) or 4,5dihydroxynaphthalene-2,7-disulfonic acid (method B). The coloured reaction product can be measured spectrophotometrically at 520 nm (method A) or 500 nm (method B).

Narayana and Ashwini proposed the determination of FUR using a measured excess of ceric ammonium sulphate (CAS) followed by the determination of unreacted oxidant using xylene cyanol FF (XC) (method A) and safranin O (SAF) (method B) [4]. The reaction mixture exhibited maximum absorbance at 612 nm (method A) and 526 nm (method B).

The combination of FUR and spironolactone is very useful in the treatment of heart failure. Spironolactone prevents hypokalaemia due to FUR in their combined dosage forms. In the view of the need in the industry for routine analysis of FUR and

spironolactone in formulation, attempts are being made to develop simple and accurate analytical methods for simultaneous estimation of FUR and Spironolactone and extend it for their determination in formulation. In this way, spectrophotometry method has been reported for the simultaneous estimation of FUR and spironolactone in combined dosage form and no method is available in the pharmacopoeias [5,6]. In both cases, the proposed methods use derivative spectroscopy.

2.2. Spectrofluorimetric methods

Buitrago et al. develops and validate an alternative analytic method by spectrofluorometry for the quality control of FUR in solid pharmaceutical forms based on the native fluorescence of the molecule in acidic medium [7].

Liu et al. found that Zn (II)-1, 4-bis (imidazol-1-ylmethyl) benzene (bix) complexes can greatly increase the fluorescence emission of FUR at 400 nm, and the enhanced fluorescence intensity is directly proportional to the concentration of FUR [8]. Based on this phenomenon, a novel spectrofluorometric method for the determination of FUR was developed, which has the advantages of simplicity, rapidity and sensitivity.

The association of FUR and amiloride furnishes a valuable natriuretic agent with a diminished kaliuretic effect, minimizing the risk of alkalosis in the treatment of refractory oedema associated with hepatic cirrhosis or congestive heart failure. Although, FUR and amiloride are usually found in commercial pharmaceutical formulations containing both drugs, in the literature there are only a few reports about its simultaneous determination. In this way, the investigation group of Peralta et al. proposed two spectrofluorimetric methods for their quantification [9,10]. In the first work, a method to separate and precisely determine both drugs is proposed; FUR and amiloride present an important fluorescence spectral interference. The approach is to separate amiloride, extracting it from the sample matrix by chemofiltration with a nylon membrane, while FUR is maintained in the filtered aqueous solution. Amioride shows low native fluorescence, but its separation and preconcentration by immobilization (solid-phase



www.ijpbs.com (or) www.ijpbsonline.com

extraction) on nylon membrane surface provides a considerable enhancement in fluorescence intensity. This study demonstrates the feasibility of using a membrane as a novel support for solid-phase extraction procedures, focused on AMI and FUR separation and determination. This nylon property is an important point to be considered when water samples are filtered via nylon discs before chromatographic determinations of AMI, especially if low concentrations are analyzed. The different behaviour of both studied drugs respect to the membrane constitutes an economic and simple separation methodology that permits to resolve spectral interferences and determine FUR and amiloride with high sensitivity and precision. The second method [10] for the sequential determination of FUR and amiloride in urine by fluorimetry is simple, efficient and allows resolving the mixture by using a solid phase extraction to suppress the background fluorescence of urine and avoid the overlap between the FUR and amiloride spectra. The use of a solidsupport, combined with the use of fluorimetry technique, contributes to enhancing both sensitivity and selectivity, so performing simultaneously the separation (retention), preconcentration detection of the analytes.

2.3. Diffuse reflectance spectroscopy

Spot tests using filter papers, coupled with diffuse reflectance spectroscopy (DRS), is a technique that uses very small quantities of reagents and solvents, making waste treatment easier and reducing costs, in accordance with the principles of Green Chemistry. The fact that spot tests are especially rapid and they minimize simple, and that reagents/solvents makes them very useful for the development of analytical methods that address the notion of Green Chemistry, which aims to develop methods and techniques that reduce or eliminate the use and generation of substances hazardous to human health or to the environment. The procedure is very simple, practical, and fast, and can be performed using portable equipment (which can be homemade) for in situ analyses. Filter paper provides a good surface for spot tests because it is composed of cellulose fibers, is very inexpensive, and is

manufactured in nearly every part of the world from renewable and recyclable resources. In this sense, Margues Luiz et al. describes the development and application of a simple, portable, and environmentally friendly method for the rapid determination of FUR in urine [11]. The method is based on the complexation reaction of furosemide (5-(aminosulfonyl)-4-chloro-2-((furanylmethyl)amino)benzoic acid, dissolved in ethanol, with FeCl₃ and the surfactant dodecyltrimethylammonium bromide (DTAB) in aqueous solution, yielding a coloured compound on the surface of a filter paper.

3. Electrochemical methods

In recent years, the electrochemical techniques have led to the advancement in the field of analysis because of their sensitivity, low cost and relatively short analysis time, as compared with other techniques. Electrochemical have proven to be useful for development of very sensitive and selective methods for the determination of organic molecules including drugs. In addition application electroanalytical techniques includes the determination of electrode mechanisms. Redox properties of drugs can give insights into their metabolic fate or their in vivo redox processes or pharmaceutical activity. On the other hand, surfactants even in trace quantities can exert a strong effect on the electrode process and the other, the has been widely electrode electrochemical studies and electro analysis for various substrates for a long time because of its stability, wide potential window and fast electron transfer rate. Shetti et al. investigated an electrochemical oxidation process of FUR on gold electrode [12]. Further, differential pulse voltammetric (DPV) method with good precision and accuracy was developed by the authors for the determination of FUR in pharmaceutical formulations. Potentiometric methods with ion-selective electrodes have proved to be effective for the analysis of pharmaceuticals and biological samples, because these sensors offer the advantages of simple design, construction, and manipulation, reasonable selectivity, fast response time, applicability to coloured and turbid solutions and possible interfacing



www.ijpbs.com (or) www.ijpbsonline.com

with automated and computerized systems. Santini et al. describes the development and application of a simple, and low-cost potentiometric 4-cloro-Nfurfuryl-5-sulphamoyl-anthranilate sensor immobilized in graphite matrix а (Pt|Hg|Hg₂(Fur)₂|Graphite [13]. The proposed potentiometric sensor is easy to prepare, exhibits long lifetime, shows high sensitivity and wide dynamic range. Good selectivity, very low detection limit, rapid response and low-cost of fabrication make this suitable for analysis of FUR pharmaceutical and biological samples.

Malode et al. develop a convenient and sensitive method for the determination of FUR by multi-walled carbon nanotubes-paraffin oil paste electrode (CNTPE) [14]. The authors report the electrochemical oxidation of FUR on CNTPE. The ability of the modified electrode for voltammetric response of selected compound was also evaluated. Finally, this modified electrode was used for the analysis of FUR in pharmaceutical and urine samples. The resulted biosensor exhibits high sensitivity, rapid response, good reproducibility and freedom of other potentially interfering species.

4. Liquid chromatography

The literature survey revealed that HPLC has been employed to detect FUR in different samples [1]. Also, FUR has been simultaneously determined with other compounds using HPLC [1]. So far, HPLC is generally the method of choice for diuretics determination, due to the required time and cost of the analysis. In **table** 1 are presented a resume of principal characteristics of methods based on HPLC.

Determination of solubility class of a drug substance according to FDA guidance is very important for the pharmaceutical companies which are taking bio waiver for the immediate release oral solid drug products. The aim of the study carried out by Kaynak and Sahin was to develop and validate an HPLC method for quantification of FUR in the samples obtained from the in vitro solubility studies performed at five different pH values (pH 1.0, 2.9, 3.9, 4.9 and 7.5). Developed and validated method was proved to be simple, reliable and also suitable as a single method for studying the solubility of FUR as a

function of pH. Finally, based on the results obtained by the authors, solubility of FUR was dependent on pH. Its solubility was low between pH 1.0 and 4.9, and was high at pH 7.5.

Kumar et al. develop a simple and sensitive direct estimation RP-HPLC method for the simultaneous determination of FUR and amiloride in plasma, for their pharmacokinetic studies and therapeutic drug monitoring [19]. Reported HPLC method involves simple single step rapid extraction procedure, economic isocratic mobile phase, and single detection wavelength for simultaneous estimation of analytes, also the run time was less than 11 minutes which allows minimal mobile phase consumption with analysis of a large number of plasma samples in a short time period. The stability of FUR and amiloride was excellent, with no evidence of degradation during sample proceeding.

Dispersive liquid—liquid microextraction (DLLME) was developed for the simultaneous determination of FUR and ethacrynic acid in human urine by HPLC [24]. DLLME is one of the most recently developed techniques of liquid phase microextraction sample preparation [25-27]. It is based on a ternary solvent system. It requires the appropriate aqueous mixing of extraction and dispersing solvents. The method is simple, fast, and low-cost and has high recovery and high enrichment factor. DLLME has many merits: fast operation, no need of large amounts of extraction solvent, high recovery, low cost, and it has easy linkage to most analytical methods.

Baranowska et al. propose the use of ultra high performance liquid chromatography (UHPLC) equipment for the fast simultaneous determination of FUR, vancomycin (antibacterial drug), spironolactone (diuretics) and terbinafine (antifungal drug) along with their metabolites in human urine and plasma [28]. The investigated metabolites were: saluamine, FUR metabolite; carnenone, active metabolite of spironolactone; N-desmethylcarboxy terbinafine, metabolite of terbinafine. The authors chosen this mixture because these drugs are often administrated to patients on Intensive Care Units. Thanks to the presented chromatographic conditions, separations of FUR, terbinafine, spironolactone and vancomycin with the metabolites can be made in 5.3 min.



www.ijpbs.com (or) www.ijpbsonline.com

Assessment of *in-vitro* Caco-2 permeability requires simultaneous quantitation of high and low permeability markers to ascertain the suitability of the method. The study developed by Patil et al. [29] represents a simple, rapid and reliable validated RP-HPLC method for the quantification of FUR, antipyrine, carbamazepine and phenytoin in presence of Hanks balanced salt solution buffer with a relatively short run time. The developed method is highly specific, accurate and precise, making it suitable for the routine analysis of these permeability markers in Caco-2 permeability study.

The determination of the RP-HPLC-DAD method for accurate measurements of 23 analyzed drugs concentrations in human urine samples from patients suffering from different illnesses was elaborated by Baranowska et al. [30]. The investigators suggested a simple method for a simultaneous and quick analysis of 23 drugs for laboratories, which did not dispose of the MS detector. Simple, fast and effective sample preparation for analysis makes it an easy decision about applying the method in a medical laboratory. This method enables the determination of the one or several analyzed drugs in one run time in urine sample from treated patients.

A rapid and cost-effective benefit micellar liquid chromatography (MLC) method coupled with UV and fluorimetric detectors has been developed to separate and quantify three frequently used cardiovascular drugs (i.e., FUR, metoprolol and verapamil) from human plasma [31]. The developed applicable for method pharmacokinetic, pharmacodynamic and therapeutic drug monitoring studies. The main advantages of the developed method are simple sample preparation and minimal use of organic solvents. In comparison with previous MLC methods for the analysis of mentioned drugs, the method has the advantage of being able to simultaneously analyze the studied drugs, in addition to the validation of the method according to FDA guidelines.

The aim of the work presented by Sora et al. consisted in the development and validation of an analytical method for assaying simultaneously FUR, spironolactone and canrenone at pharmacokinetic concentration levels in plasma samples, based on a programmed bimodal functioning of the MS/MS

detection (negative ion mode for FUR, positive ion mode for spironolactone and canrenone) [33]. The method was successfully applied to a bioequivalence study for immediate release pharmaceutical oral dosage forms (capsules) containing 20 mg of FUR and 50 mg of spironolactone in fasting conditions.

In other aspect, most of the methods published are limited for assaying diuretics in urine, plasma and bovine milk; there are few methods for the simultaneous analysis of diuretics adulteration in foods and dietary supplements. In order to ban the sales of adulterated products effectively, it is necessary to develop a fast and reliable method for screening suspicious dietary supplements. In the study developed by Woo et al., the authors report validated methods for the simultaneous analysis of 17 diuretics, including FUR, in dietary supplements by HPLC-UV and LC-MS/MS [34]. Developed HPLC-UV and LC-MS/MS methods permit the simultaneous analysis of a large number of diuretics in dietary supplement matrices with a minimum of sample preparation.

5. Thin Layer Chromatography

Due to no reported HPTLC method estimation of FUR spironolactone in tablet, consideration the simplicity, cost effectiveness and reliability of HPTLC in the analysis of drugs, Kher et al. develop a new, simple and validated HPTLC method for simultaneous estimation of FUR and spironolatone dosage form tablets [35]. The HPTLC method was subjected to statistical validation and was applied for the determination of FUR and spironolactone from its combined dosage form. In this study, stability of FUR and spironolactone in present dosage form was ICH established through employment of recommended stress condition. The developed procedure has been evaluated over the specificity, linearity, accuracy, precision and robustness in order to ascertain the stability of the analytical method.

6. Stability indicating methods

The stability of a pharmaceutical preparation is defined by its resistance to the various chemical, physical, and microbiological reactions that may



www.ijpbs.com (or) www.ijpbsonline.com

change their original properties during transport, storage, and use. Chemical degradation may result in a loss of potency or an increase in drug toxicity, so that clinical use of a pharmaceutical preparation must be unacceptable if the degradation is relatively high. When a drug dosage form is altered (by dissolution, pulverization, or addition to other materials) or the environment of the drug is modified by changes in storage conditions, the stability of the drug may be affected.

A stability indicating method is a quantitative test method that can detect possible degradants and impurities of drug substance (API) and drug products, normally using HPLC. Stability information is needed for regulatory submissions such as IND

IJPBS | Volume 3 | Issue 4 | OCT-DEC | 2013 | 168-181

(Investigational New Drug Application) and NDA (New Drug Applications) and to set expiration dates for the API or drug product.

On the other hand, the forced degradation studies are another very important part of the validation of the stability indicating method. In forced degradation studies, samples are tested under extreme conditions (acid, base, peroxide, heat, light, humidity etc) in order to rapidly screen drug product stabilities.

In this way, diverse works have been published about studies of stability of FUR, alone or in mixture with other drugs, which use HPLC methods [36-39]. The principal aspects of this investigation are summarized in **Table 2**.

Table 2: Stability indicating HPLC methods

Compounds Procedure Conclusions Ref.						
Procedure	Conclusions	Ref.				
Waters C ₁₈ ; KH ₂ PO ₄ : methanol	Extemporaneously compounded FUR	36				
(70:30) and citric acid solution to	suspensions, 2 mg ml ⁻¹ , were stable for at least 60					
adjust pH to 5.5; at 1ml min ⁻¹ ; at	days stored in glass bottles protected from light					
235 nm; injection volume 20 μl	at 4, 30 and 45° C					
C ₁₈ ; acetonitrile:50 mM phosphate	The stability studied indicated that the drugs are	37				
buffer (pH 3) (50:50); at 26°C; at 1	susceptible to wet heat, dry heat, day light, acidic					
ml min ⁻¹ ; at 283 nm; injection	and alkaline conditions with maximum					
volume 10 μl	degradation in oxidation degradation					
Shim-pack VP-ODS C ₁₈ ;	After 20 h at room temperature, individually, FUR	38				
acetonitrile:phosphate buffer (pH	and APN added to 20% mannitol and 0.9% NaCl					
7.0) (30:70); at 0.6 ml min ⁻¹ ; at 228						
nm and 275 nm; at 25 °C; injection	tion when FUR and APN were combined in the same					
volume 20 μL	parenteral solutions, the behaviour of FUR was					
	similar to the behaviour observed for the drug					
	individually in the same solutions					
SGE SS Wakosil II C ₈ ;	The stability of FUR and spironolactone in present	39				
acetonitrile:ammonium acetate	dosage forms was established through					
buffer pH 3.9 (50:50); at 1.0 ml	employment of ICH recommended stress					
min ⁻¹ ; at 254 nm	conditions					
	Procedure Waters C ₁₈ ; KH ₂ PO ₄ : methanol (70:30) and citric acid solution to adjust pH to 5.5; at 1ml min ⁻¹ ; at 235 nm; injection volume 20 μl C ₁₈ ; acetonitrile:50 mM phosphate buffer (pH 3) (50:50); at 26°C; at 1 ml min ⁻¹ ; at 283 nm; injection volume 10 μl Shim-pack VP–ODS C ₁₈ ; acetonitrile:phosphate buffer (pH 7.0) (30:70); at 0.6 ml min ⁻¹ ; at 228 nm and 275 nm; at 25 °C; injection volume 20 μL SGE SS Wakosil II C ₈ ; acetonitrile:ammonium acetate buffer pH 3.9 (50:50); at 1.0 ml	Waters C ₁₈ ; KH ₂ PO ₄ : methanol (70:30) and citric acid solution to adjust pH to 5.5; at 1ml min ⁻¹ ; at 235 nm; injection volume 20 μl at 4, 30 and 45°C C ₁₈ ; acetonitrile:50 mM phosphate buffer (pH 3) (50:50); at 26°C; at 1 susceptible to wet heat, dry heat, day light, acidic and alkaline conditions with maximum volume 10 μl degradation in oxidation degradation Shim-pack VP—ODS C ₁₈ ; After 20 h at room temperature, individually, FUR acetonitrile:phosphate buffer (pH 7.0) (30:70); at 0.6 ml min ⁻¹ ; at 228 nm and 275 nm; at 25 °C; injection volume 20 μL when the same parenteral solutions, the behaviour of FUR was similar to the behaviour observed for the drug individually in the same solutions SGE SS Wakosil II C ₈ ; The stability of FUR and spironolactone in present dosage forms was established through buffer pH 3.9 (50:50); at 1.0 ml				

7. CONCLUSIONS

This work is an actualized revision of the work published in 2008 [1], about analytical determination of FUR. The overview includes the most relevant analytical determinations classified in the following types: Optical methods, electrochemical methods, liquid chromatography and thin layer

chromatography. Also, we are enclosed a section about stability indicating methods. As can be seen from the **Figure 1** a similar number of publication have appeared in last two decades, being the year 2005 where more determinations of furosemide were published in the literature.






Figure 1: Number of publications from last two decades

REFERENCES

- [1] Espinosa Bosch M, Ruiz Sánchez AJ, Sánchez Rojas F, Bosch Ojeda C. Recent developments in analytical determination of furosemide. J Pharm Biomed Anal 2008; 48:519–532.
- [2] Tharpa K, Basavalah K, Vinay KB. Spectrophotometric determination of furosemide in pharmaceuticals using permanganate. Jordan J Chem 2009; 4:387–397.
- [3] Tharpa K, Basavalah K, Vinay KB. Use of diazocoupling reaction for sensitive and selective spectrophotometric determination of furosemide in spiked human urine and pharmaceuticals. Chem papers 2010; 64:415–423.
- [4] Narayana B, Ashwini K. Spectrophotometric determination of furosemide by its oxidation with ceric ammonium sulphate. Indian J Chem Technol 2010; 17:150–153.
- [5] Patel H, Solanki S. Development and validation of spectrophotometric methods for simultaneous estimation of furosemide and spironolactone in combined tablet dosage form. Inter J Phar Pharma Sci 2012; 4:383–386.
- [6] Reddy ASSV, Ahmed M, Shetty ASK. Simultaneous determination and validation of spironolactone and furosemide by second order derivative method and area under curve method in bulk drug and pharmaceutical formulations. Int J Chem Tech Res 2013; 5:1876–1885.
- [7] Buitrago A, Calderón L, León A, Brunetto R, Gallignani M. Desarrollo y validación de un método espectrofluorimétrico para la determinación de furosemida en formas farmacéuticas sólidas. Avances Quim 2010; 5:15–25.

- [8] Liu Y, Wang H, Wang J, Li Y. A simple and sensitive spectrofluorimetric method for the determination of furosemide using zinc(II)-1,4-bis(imidazole-1ylmethyl)benzene complexes. Luminiscence 2012; doi: 10.1002/bio.2451.
- [9] Peralta CM, Fernández LP, Masi AN. A novel application of immobilization on membranes for the separation and spectrofluorimetric quantification of amiloride and furosemide in pharmaceutical samples. Anal Chim Acta 2010; 661:85–90.
- [10] Peralta CM, Fernández LP, Masi AN. Solid phase extraction using nylon membranes with fluorescence detection as a fast and sensitive method for amiloride and furosemide determination in urine samples. Microchem J 2011; 98:39–43.
- [11] Luiz VHM, pezza L, Pezza HR. Rapid determination of furosemide by combined spot test/diffuse reflectance spectroscopy to detect doping in sport. Microchem J 2013; 109:68–72.
- [12] Shetti NP, Sampangi LV, Hegde RN, Nandibewoor ST. Electrochemical oxidation of loop diuretic furosemide at gold electrode and its analytical applications. Int J Electrochem Sci 2009; 4:104–121.
- [13] Santini AO, Pezza HR, Sequinel R, Rufino JL, Pezza L. Potentiometric sensor for furosemide determination in pharmaceuticals, urine, blood serum and bovine milk. J Braz Chem Soc 2009; 20:64–73.
- [14] Malode SJ, Abbar JC, Shetti NP, Nandibewoor ST. Voltammetric oxidation and determination of loop diuretic furosemide at a multi-walled carbon nanotubes paste electrode. Electrochim Acta 2012; 60:95–101.



www.ijpbs.com (or) www.ijpbsonline.com

- [15] Soica C, Imre S, vari C, Gyeresi A, dehelean C, Dogaru M. HPLC analysis of furosemide in rat plasma. Bioavailability study. Note 1. Farmacia 2008; 4:419–427.
- [16] Youm I, Youan BBC. Validated reverse-phase high-performance liquid chromatography for quantification of furosemide in tablets and nanoparticles. J Anal Meth Chem 2013; Article ID 207028, 9 pages, http://dx.doi.org/10.1155/2013/207028.
- [17] Kaynak MS, Sahin S. Development and validation of a RP-HPLC method for determination of solubility of furosemide. Turk J Pharm Sci 2013; 10:25–34.
- [18] Nagori BP, Solanki R. RP-HPLC method for simultaneous estimation of frusemide and amiloride hydrochloride in tablet formulation. Indian J Pharm Sci 2010; 72:384–387.
- [19] Kumar M, Amin R, patel DR, Shah RJ, Amin JM, Jain N, Jain DK. Estimation of amiloride and furosemide in human plasma using high performance liquid chromatography. Der Pharmacia Sinica 2010; 1:117–125.
- [20] Patel H, Solanki S. Simultaneous estimation of furosemide and spironolactone in combined pharmaceutical dosage form by RP_HPLC. Asian J Pharm Clin Res 2012; 5:195–198.
- [21] Maulik B, ketan D, Shital F. development and validation of RP_HPLC method for simultaneous estimation of furosemide and spironolactone in their combined tablet dosage form. J Pharm Sci Biosci Res 2012; 2:144–147.
- [22] Walash MI, El-Enany N, Eid MI, Fathy ME. Micellar high performance liquid chromatographic determination of furosemide and spironolactone in combined dosage forms. Application to human plasma. J Pharm Res 2012; 5:2648–2656.
- [23] Sultana N, Shamim S, Gul MAS. Simultaneous determination of gemifloxacin and diuretics in bulk, pharmaceutical dosage forms and human serum by RP HPLC. Quim Nova 2010; 33:1590–1593.
- [24] Han D, tang B, Row KH. Determination of diuretic drugs in human urine using dispersive liquid-liquid microextraction by high performance liquid chromatography. J Liquid Chrom Rel technol 2013; 36:2069–2081.
- [25] Bosch Ojeda C, Sánchez Rojas F. Separation and preconcentration by dispersive liquid-liquid microextraction procedure: a review. Chromatographia 2009; 69:1149–1159.
- [26] Bosch Ojeda C, Sánchez Rojas F. Separation and preconcentration by dispersive liquid-liquid microextraction procedure: recent applications. Chromatographia 2011; 74:651–679.

IJPBS | Volume 3 | Issue 4 | OCT-DEC | 2013 | 168-181

- [27] Herrera-Herrera AV, Asensio-Ramos M, hernández-Borges J, Rodríguez-Delgado MA. Dispersive liquid-liquid microextraction for determination of organic analytes. Trends Anal Chem 2010; 29:728–751.
- [28] Baranowska I, Wilczek A, Baranowski J. Rapid UHPLC method for simultaneous determination of vancomycin, terbinafine, spironolactone, furosemide and their metabolites: Application to human plasma and urine. Anal Sci 2010; 26:755–759.
- [29] Patil SR, Kumar L, Kohli G, Bansal AK. Validated HPLC method for concurrent determination of antipyrine, carbamazepine, furosemide and phenytoin and its application in assessment of drug permeability through Caco-2 cell monolayers. Sci Pharm 2012; 80:89–100.
- [30] Baranowska I, Markowski P, Baranowski J. Development and validation of an HPLC method for the simultaneous analysis of 23 selected drugs belonging to different therapeutic groups in human urine samples. Anal Sci 2009; 25:1307–1313
- [31] Soltani S, Jouyban A. A validated micellar LC method for simultaneous determination of furosemide, metoprolol and verapamil in human plasma. Bioanal 2012; 4:41–48.
- [32] Blanco MD, Bennani A, Alcaraz A, Martínez P, Tovar I, Cañizares F. Evaluación de un método de cuantificación de la concentración de furosemida por cromatografía en fase líquida de alta resolución. Quim Clin 2007; 26:45–48.
- [33] Sora DI, Udrescu S, Albu F, David V, Medvedovici A. Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples. J Pharm Biomed Anal 2010; 52:734–740.
- [34] Woo H, Kim JW, Han KM, Lee JH, Hwang LS, lee JH, Kim J, Kweon SJ, Cho S, Chae KR, Han SY, Kim J. Simultaneous analysis of 17 diuretics in dietary supplements by HPLC and LC-MS/MS. Food Additives Contam 2013; 30:209–217.
- [35] Kher G, Ram V, Kher M, Joshi H. Development and validation of HPTLC method for simultaneous determination of furosemide and spironolactone in its tablet formulation. Res J Pharm Biol Chem Sci 2013;
- [36] Shoosanglertwijit J, Kaewnopparat S, Yongmaitreesakul B, Pattayananthavej S, Kaewnopparat N. Physical, chemical, and microbiological stability of extemporaneous furosemide suspensions. Asian Biomed 2011; 5:681–686.
- [37] Solanki R. Stability indicating RP_HPLC method for simultaneous determination of frusemide and amiloride hydrochloride in tablet dosage form. Int J Adv Pharm Anal 2011; 1:16–23.

www.ijpbs.com (or) www.ijpbsonline.com

[38] Dos Santos CA, Mazzola PG, Polacwiecz B, Knirsch MC, Cholewa O, Penna TCV. Stability of furosemide and aminophylline in parenteral solutions. Braz J Pharm Sci 2011; 47:89–96.

IJPBS | Volume 3 | Issue 4 | OCT-DEC | 2013 | 168-181

[39] Ram VR, Dave PN, Joshi HS. Development and validation of a stability-indicating HPLC assay method for simultaneous determination of spironolactone and furosemide in tablet formulation. J Chrom Sci 2012; 50:721–726.



*Corresponding Author:

F. Sánchez Rojas*

Department of Analytical Chemistry, Faculty of Sciences, University of Málaga, Campus Teatinos, 29071 Málaga, Spain